Company intelligence / Profile preview

City Therapeutics

Cambridge, Massachusetts, United Statescitytx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Company is in pre-clinical stage with first program expected to enter clinical development around the end of 2025. They have a strategic collaboration with Bausch + Lomb for an RNAi therapy for retinal diseases.

Therapeutic areas: OtherOphthalmology
Modalities: RNAi therapeuticssmall interfering RNAs (siRNAs)
Industry: Biotech

Drug pipeline

3 assets

CITY-FXI

2 more assets in the full pipeline.

Request access →

Partnerships

Bausch + Lomb (for retinal diseases including geographic atrophy)

Beyond the preview

Go deeper on City Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on City Therapeutics.

Explore the full profile